Colistimethate sodium: Difference between revisions
| Line 27: | Line 27: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most strains of the microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section | |||
==References== | ==References== | ||
Revision as of 02:20, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Colistimethate sodium (polymyxin E) is a polymyxin antibiotic produced by certain strains of Bacillus polymyxa var. colistinus. Colistin is a mixture of cyclic polypeptides colistin A and B. Colistin is effective against most Gram-negative bacilli and is used as a polypeptide antibiotic.
Colistimethate sodium is a decades-old drug that fell out of favor due to its nephrotoxicity. It remains one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter.[1] NDM-1 metallo-β-lactamase multidrug-resistant Enterobacteriaceae have also shown susceptibility to Colistin.[2]
Category
US Brand Names
COLY-MYCIN M®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied
Mechanism of Action
Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most strains of the microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section
References
- ↑ Falagas, ME; Grammatikos, AP; Michalopoulos, A (2008). "Potential of old-generation antibiotics to address current need for new antibiotics". Expert review of anti-infective therapy. 6 (5): 593–600. doi:10.1586/14787210.6.5.593. PMID 18847400. Unknown parameter
|month=ignored (help); Unknown parameter|author-separator=ignored (help) - ↑ Kumarasamy; Toleman, Mark A; Walsh, Timothy R; Bagaria, Jay; Butt, Fafhana; Balakrishnan, Ravikumar; Chaudhary, Uma; Doumith, Michel; Giske, Christian G; et al. (2010). "Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study". The Lancet Infectious Diseases. 10 (9): 597–602. doi:10.1016/S1473-3099(10)70143-2. PMC 2933358. PMID 20705517.